Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Intracranial CD1c/CD141 myeloid dendritic cells with ipilimumab & nivolumab in high-grade glioma

Bart Neyns • 13 Sep 2024
ESMO 2024
Brain Tumor Glioma Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab

Bart Neyns, MD, PhD, Universitair Ziekenhuis Brussel, Brussels, Belgium, discusses findings from a Phase I trial (NCT03233152) of intracranial administration of nivolumab, ipilimumab, and autologous myeloid dendritic cells (myDC) in patients with recurrent high-grade glioma (rHGG) following tumor resection. The study found that this approach is safe and well-tolerated, warranting further studies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bart Neyns

The rationale for dendritic cell therapy in recurrent glioblastoma
2:02
The rationale for dendritic cell therapy in recurrent glioblastoma
Bart Neyns • 13 Sep 2024
Safety of intracranial CD1c/CD141 and checkpoint inhibitors in rHGG
2:12
Safety of intracranial CD1c/CD141 and checkpoint inhibitors in rHGG
Bart Neyns • 13 Sep 2024

Related Videos

Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
0:58
Practical challenges of adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
1:51
TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma
Tolga Tuncer • 30 May 2026
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
1:32
Phase II trial of lutetium-177 dotatate in advanced intracranial meningioma
Sylvia Kurz • 31 May 2026
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
1:04
Mechanism of 177Lu-dotatate in SSTR2-positive meningioma
Sylvia Kurz • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals